Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Johnson & Johnson

Pharma sales down, device sales up.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

J&J 1Q

1Q Revenues: $15.6 billion (+4%)

1Q Earnings: $4.5 billion (+29%)

Comments: Earnings were boosted by a $910 million one-time gain from litigation. Worldwide pharma sales fell 2% to $5.6 billion, aided by a 3% boost from currency fluctuation. Domestic pharma sales dropped 13%. Consumer sales were $3.8 billion (+1%, with a 5% boost from currency), with domestic sales down 9%. Worldwide device sales were up 13% (incl. 4% from currency) to $6.2 billion, with domestic sales up 9%. Pharma sales were driven by Remicade, up 15% to $1.2 billion. Velcade sales grew 36% (international only) to $261 million. Prezista sales were up 53% to $187 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters